The report provides an overview
of the approved therapies for AML, MDS, unmet need and limitations of the
current SOC for relapsed and refractory pts. The report highlights the
competition and commercial opportunity in pursuing this therapy area -
Comprehensive list of the early and late stage drugs in the clinic, their MoA
and the companies developing them.
Detailed financial and
competitive analysis of the companies leading in the race to launch new
therapies for this indication - Ambit Biosciences, Onconova Therapeutics,
SymBio Pharma, and Celgene are available as a separate or with the full rep
...
Read more »
